| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
REPORT |
1 UCLA Medical School, Los Angeles, USA
2 Presbyterian Hospital, Dallas, USA
3 Koch Institute, Berlin, Germany
4 FDA, Washington DC, USA
Correspondence to:
Correspondence to:
Dr D E Furst, 1000 Veteran Avenue Rehab Center, Rn 32-59, Los Angeles, CA 90095, USA;
defurst@mednet.ucla.edu
Keywords: guidelines; rheumatoid arthritis; tuberculosis
| The first 150 words of the full text of this article appear below. |
ACTIVE TUBERCULOSIS
Definition
Clinically suspicious circumstances associated with bacteriological positivity, using standard techniques and including resistance testing when feasible. Note: This does not apply to children, where AFB culture may be negative.
Action: 4 Drug treatment
Class A Evidence
LATENT TUBERCULOSIS
Definition
Requires both "1" and "2":
1 No signs or symptoms but in the presence of any of the following risk factors:
2 A positive PPD—(intermediate strength, irrespective of past BCG use). "For persons with HIV infection, who are receiving immunosuppressive therapy, who have had recent close contact with persons with infectious tuberculosis or who have abnormal chest radiographs consistent with prior tuberculosis, 5 mm of
This article has been cited by other articles:
|
|
 |
|
  G. Hatemi, M. Melikoglu, N. Sut, and H. Yazici Purified protein derivative reaction is not augmented in Behcet's syndrome patients Rheumatology, May 1, 2008; 47(5): 733 - 734. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sellam, H. Hamdi, C. Roy, G. Baron, M. Lemann, X. Puechal, M. Breban, F. Berenbaum, M. Humbert, K. Weldingh, et al. Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy Ann Rheum Dis, December 1, 2007; 66(12): 1610 - 1615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. P. Sfikakis, N. Markomichelakis, E. Alpsoy, S. Assaad-Khalil, B. Bodaghi, A. Gul, S. Ohno, N. Pipitone, M. Schirmer, M. Stanford, et al. Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations Rheumatology, May 1, 2007; 46(5): 736 - 741. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Noguera-Pons, J. Borras-Blasco, I. Romero-Crespo, R. Anton-Torres, A. Navarro-Ruiz, and J. A. Gonzalez-Ferrandez Optic Neuritis with Concurrent Etanercept and Isoniazid Therapy Ann. Pharmacother., December 1, 2005; 39(12): 2131 - 2134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Doan and E. Massarotti Rheumatoid Arthritis: An Overview of New and Emerging Therapies J. Clin. Pharmacol., July 1, 2005; 45(7): 751 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Olsen and C. M. Stein New Drugs for Rheumatoid Arthritis N. Engl. J. Med., May 20, 2004; 350(21): 2167 - 2179. [Full Text] [PDF]
|
|
|
|
|
|
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, M Dougados, P Emery, A Gibofsky, A F Kavenaugh, E C Keystone, et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003) Ann Rheum Dis, November 1, 2003; 62(90002): ii2 - 9. [Full Text] [PDF]
|
|
|
|
|
|
S Ehlers Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF Ann Rheum Dis, November 1, 2003; 62(90002): ii37 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X Mariette, D Salmon, and Group RATIO French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers Ann Rheum Dis, August 1, 2003; 62(8): 791 - 791. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
